Search research articles
Contact Us
Filters
Showing results (161-170 of 175) with videos related to
Page
of 18
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 25, 2009
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
J-C Soria, F A Shepherd, J-Y Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 1, 2017
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer
M-S Tsao, G Le Teuff, F A Shepherd, et al.
Thrombosis Research
|
June 9, 2026
Novel germline genetic variants associated with venous thrombo-embolism (VTE) and arterial thrombo-embolism (ATE) risk in patients with ALK and ROS1 fusion non-small cell lung cancer (NSCLC)
S Khan, B Jimenez Munarriz, K Hueniken, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
N Murray, R B Livingston, F A Shepherd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 3, 2018
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
G Goss, C-M Tsai, F A Shepherd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 15, 2014
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
G V Scagliotti, I Bondarenko, F Blackhall, et al.
British Journal of Cancer
|
July 19, 2012
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
I Diaz-Padilla, L L Siu, M San Pedro-Salcedo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 1999
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
J von Pawel, J H Schiller, F A Shepherd, et al.
Current Oncology (Toronto, Ont.)
|
December 31, 2020
Longitudinal health utilities, symptoms and toxicities in patients with <i>ALK-</i>rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment
B C Tse, B I Said, Z J Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2001
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study
M Schuler, R Herrmann, J L De Greve, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 175) with videos related to
Sort By:
Page
of 18
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 25, 2009
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
J-C Soria, F A Shepherd, J-Y Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 1, 2017
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer
M-S Tsao, G Le Teuff, F A Shepherd, et al.
Thrombosis Research
|
June 9, 2026
Novel germline genetic variants associated with venous thrombo-embolism (VTE) and arterial thrombo-embolism (ATE) risk in patients with ALK and ROS1 fusion non-small cell lung cancer (NSCLC)
S Khan, B Jimenez Munarriz, K Hueniken, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
N Murray, R B Livingston, F A Shepherd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 3, 2018
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
G Goss, C-M Tsai, F A Shepherd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 15, 2014
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
G V Scagliotti, I Bondarenko, F Blackhall, et al.
British Journal of Cancer
|
July 19, 2012
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
I Diaz-Padilla, L L Siu, M San Pedro-Salcedo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 1999
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
J von Pawel, J H Schiller, F A Shepherd, et al.
Current Oncology (Toronto, Ont.)
|
December 31, 2020
Longitudinal health utilities, symptoms and toxicities in patients with <i>ALK-</i>rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment
B C Tse, B I Said, Z J Fan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2001
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study
M Schuler, R Herrmann, J L De Greve, et al.
Page
of 18